Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

65 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Polygenic risk score and risk of monoclonal B-cell lymphocytosis in caucasians and risk of chronic lymphocytic leukemia (CLL) in African Americans.
Kleinstern G, Weinberg JB, Parikh SA, Braggio E, Achenbach SJ, Robinson DP, Norman AD, Rabe KG, Boddicker NJ, Vachon CM, Lesnick CE, Call TG, Brander DM, Rassenti LZ, Kipps TJ, Olson JE, Cerhan JR, Kay NE, Furman RR, Hanson CA, Shanafelt TD, Slager SL. Kleinstern G, et al. Among authors: brander dm. Leukemia. 2022 Jan;36(1):119-125. doi: 10.1038/s41375-021-01344-9. Epub 2021 Jul 20. Leukemia. 2022. PMID: 34285341 Free PMC article.
Ofatumumab monotherapy as a consolidation strategy in patients with previously untreated chronic lymphocytic leukaemia: a phase 2 trial.
Strati P, Lanasa M, Call TG, Leis JF, Brander DM, LaPlant BR, Pettinger AM, Ding W, Parikh SA, Hanson CA, Chanan-Khan AA, Bowen DA, Conte M, Kay NE, Shanafelt TD. Strati P, et al. Among authors: brander dm. Lancet Haematol. 2016 Sep;3(9):e407-14. doi: 10.1016/S2352-3026(16)30064-3. Epub 2016 Aug 1. Lancet Haematol. 2016. PMID: 27570087 Clinical Trial.
Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1b study.
Seymour JF, Ma S, Brander DM, Choi MY, Barrientos J, Davids MS, Anderson MA, Beaven AW, Rosen ST, Tam CS, Prine B, Agarwal SK, Munasinghe W, Zhu M, Lash LL, Desai M, Cerri E, Verdugo M, Kim SY, Humerickhouse RA, Gordon GB, Kipps TJ, Roberts AW. Seymour JF, et al. Among authors: brander dm. Lancet Oncol. 2017 Feb;18(2):230-240. doi: 10.1016/S1470-2045(17)30012-8. Epub 2017 Jan 13. Lancet Oncol. 2017. PMID: 28089635 Free PMC article. Clinical Trial.
Real-world outcomes and management strategies for venetoclax-treated chronic lymphocytic leukemia patients in the United States.
Mato AR, Thompson M, Allan JN, Brander DM, Pagel JM, Ujjani CS, Hill BT, Lamanna N, Lansigan F, Jacobs R, Shadman M, Skarbnik AP, Pu JJ, Barr PM, Sehgal AR, Cheson BD, Zent CS, Tuncer HH, Schuster SJ, Pickens PV, Shah NN, Goy A, Winter AM, Garcia C, Kennard K, Isaac K, Dorsey C, Gashonia LM, Singavi AK, Roeker LE, Zelenetz A, Williams A, Howlett C, Weissbrot H, Ali N, Khajavian S, Sitlinger A, Tranchito E, Rhodes J, Felsenfeld J, Bailey N, Patel B, Burns TF, Yacur M, Malhotra M, Svoboda J, Furman RR, Nabhan C. Mato AR, et al. Among authors: brander dm. Haematologica. 2018 Sep;103(9):1511-1517. doi: 10.3324/haematol.2018.193615. Epub 2018 Jun 7. Haematologica. 2018. PMID: 29880613 Free PMC article.
Outcomes of front-line ibrutinib treated CLL patients excluded from landmark clinical trial.
Mato AR, Roeker LE, Allan JN, Pagel JM, Brander DM, Hill BT, Cheson BD, Furman RR, Lamanna N, Tam CS, Handunnetti S, Jacobs R, Lansigan F, Bhavsar E, Barr PM, Shadman M, Skarbnik AP, Goy A, Beach DF, Svoboda J, Pu JJ, Sehgal AR, Zent CS, Tuncer HH, Schuster SJ, Pickens PV, Shah NN, Rhodes J, Ujjani CS, Nabhan C. Mato AR, et al. Among authors: brander dm. Am J Hematol. 2018 Nov;93(11):1394-1401. doi: 10.1002/ajh.25261. Epub 2018 Sep 26. Am J Hematol. 2018. PMID: 30132965 Free PMC article.
SET alpha and SET beta mRNA isoforms in chronic lymphocytic leukaemia.
Brander DM, Friedman DR, Volkheimer AD, Christensen DJ, Rassenti LZ, Kipps TJ, Guadalupe E, Chen Y, Zhang D, Wang X, Davis C, Owzar K, Weinberg JB. Brander DM, et al. Br J Haematol. 2019 Feb;184(4):605-615. doi: 10.1111/bjh.15677. Epub 2018 Nov 15. Br J Haematol. 2019. PMID: 30443898 Free PMC article. Clinical Trial.
Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL.
Woyach JA, Ruppert AS, Heerema NA, Zhao W, Booth AM, Ding W, Bartlett NL, Brander DM, Barr PM, Rogers KA, Parikh SA, Coutre S, Hurria A, Brown JR, Lozanski G, Blachly JS, Ozer HG, Major-Elechi B, Fruth B, Nattam S, Larson RA, Erba H, Litzow M, Owen C, Kuzma C, Abramson JS, Little RF, Smith SE, Stone RM, Mandrekar SJ, Byrd JC. Woyach JA, et al. Among authors: brander dm. N Engl J Med. 2018 Dec 27;379(26):2517-2528. doi: 10.1056/NEJMoa1812836. Epub 2018 Dec 1. N Engl J Med. 2018. PMID: 30501481 Free PMC article. Clinical Trial.
NCCN Guidelines Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 2.2019.
Wierda WG, Byrd JC, Abramson JS, Bilgrami SF, Bociek G, Brander D, Brown J, Chanan-Khan AA, Chavez JC, Coutre SE, Davis RS, Fletcher CD, Hill B, Kahl BS, Kamdar M, Kaplan LD, Khan N, Kipps TJ, Ma S, Malek S, Mato A, Mosse C, Neppalli VT, Shadman M, Siddiqi T, Stephens D, Wagner N, Dwyer MA, Sundar H. Wierda WG, et al. J Natl Compr Canc Netw. 2019 Jan;17(1):12-20. doi: 10.6004/jnccn.2019.0002. J Natl Compr Canc Netw. 2019. PMID: 30659125
65 results